. 2017 Feb 23;7:43118. doi: 10.1038/srep43118

Table 2. Biodistribution of ¹¹¹In-DOTA-3A3 and ¹¹¹In-DOTA-TAT in Balb/c nu/nu mice bearing BxPC-3 xenografts 24 h after iv injections with 40 μg of conjugates.

	Radioactivity uptake
	¹¹¹In-DOTA-3A3	¹¹¹In-DOTA-TAT
Blood	0.6 ± 0.2	4.6 ± 0.3^a
Salivary glands	3.0 ± 0.2^a	1.5 ± 0.2
Lung	1.7 ± 0.2	2.6 ± 0.2^a
Liver	14.6 ± 1.0	18.5 ± 0.8^a
Spleen	4 ± 2	14 ± 3^a
Stomach	1.2 ± 0.5^a	0.59 ± 0.05
Small intestine wall	6 ± 1^a	0.8 ± 0.1
Kidney	30 ± 4^a	20 ± 2
Tumour	5.3 ± 0.7^a	2.4 ± 0.2
Muscle	0.5 ± 0.1	0.50 ± 0.04
Bone	1.2 ± 0.3^a	0.86 ± 0.10
GI^b	5.8 ± 0.3^a	1.4 ± 0.3
Carcass^b	16.6 ± 0.3^a	13 ± 1
	Tumour to organ ratio
Tumour/blood	10 ± 2^a	0.52 ± 0.05
Tumour/muscle	12 ± 3^a	4.9 ± 0.5

Results for radioactivity uptake in tissues are presented as average of percent injected dose per gram tissue (%ID/g) for 4 animals ± SD. Data were assessed by an unpaired, two-tailed t-test in order to determine significant differences (P < 0.05). ^aValue is significantly higher ^bValues for GI (gastrointestinal) tract and carcass are given as %ID per whole sample.

Table 2. Biodistribution of 111In-DOTA-3A3 and 111In-DOTA-TAT in Balb/c nu/nu mice bearing BxPC-3 xenografts 24 h after iv injections with 40 μg of conjugates.

Table 2. Biodistribution of ¹¹¹In-DOTA-3A3 and ¹¹¹In-DOTA-TAT in Balb/c nu/nu mice bearing BxPC-3 xenografts 24 h after iv injections with 40 μg of conjugates.